Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#51 / 100 Total
SION - Sionna Therapeutics Inc - Stock Price Chart
TickerSION [NASD, RUT]
CompanySionna Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap924.85MEPS (ttm)-
P/E-EPS this Y83.43%
Forward P/E-EPS next Y-8.40%
PEG-EPS past 5Y-
P/S-EPS next 5Y40.90%
P/B2.63EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own46.56%Inst Own54.08%
Insider Trans20.75%Inst Trans39.33%
Short Float12.02%EarningsMay 12/b
Analyst Recom1.00Target Price38.50
Avg Volume180.78K52W Range7.26 - 25.19
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TPG GP A, LLC10% OwnerJun 27 '25Buy15.8460,000950,4006,744,962Jul 01 05:03 PM
TPG GP A, LLC10% OwnerFeb 10 '25Buy18.001,125,00020,250,0006,684,962Feb 12 05:21 PM
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 10 '25Buy18.001,125,00020,250,0006,923,365Feb 10 05:04 PM
ORBIMED ADVISORS LLCDirectorFeb 10 '25Buy18.00550,0009,900,0003,704,959Feb 10 04:28 PM
Thompson Peter A.DirectorFeb 10 '25Buy18.00550,0009,900,0003,704,959Feb 10 04:05 PM
ANNX - Annexon Inc - Stock Price Chart
TickerANNX [NASD, RUT]
CompanyAnnexon Inc
CountryUSA
IndustryBiotechnology
Market Cap299.52MEPS (ttm)-1.17
P/E-EPS this Y-45.07%
Forward P/E-EPS next Y1.20%
PEG-EPS past 5Y-0.09%
P/S-EPS next 5Y2.82%
P/B1.23EPS Q/Q-78.85%
Dividend-Sales Q/Q-
Insider Own12.93%Inst Own87.98%
Insider Trans-0.27%Inst Trans-5.92%
Short Float10.60%EarningsMay 12/b
Analyst Recom1.00Target Price11.60
Avg Volume1.60M52W Range1.28 - 7.85
Jun-18-25 04:05PM Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) (GlobeNewswire)
May-29-25 04:05PM Annexon Biosciences to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.39% -6.42%
May-19-25 04:05PM Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
04:05PM Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barre Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
May-16-25 04:05PM Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.05%
May-12-25 08:00AM Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +10.62%
May-09-25 05:00PM Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire) -5.88%
05:00PM Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire)
May-07-25 08:00AM Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress (GlobeNewswire)
Apr-16-25 04:05PM Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carson William H.DirectorJun 30 '25Buy2.464,11510,12329,715Jul 01 04:55 PM
Dananberg JamieCHIEF MEDICAL OFFICERFeb 18 '25Sale2.965,52116,34233,479Feb 20 04:54 PM
ARTIS DEAN RICHARDEVP & CHIEF SCIENTIFIC OFFICERFeb 18 '25Sale2.975,51516,38083,814Feb 20 04:52 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 18 '25Sale2.918,34524,28461,237Feb 20 04:51 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 18 '25Sale2.956,61819,52386,579Feb 20 04:49 PM
KFS - Kingsway Financial Services Inc - Stock Price Chart
TickerKFS [NYSE, RUT]
CompanyKingsway Financial Services Inc
CountryUSA
IndustryAuto & Truck Dealerships
Market Cap467.75MEPS (ttm)-0.37
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-5.78%
P/S4.08EPS next 5Y-
P/B80.49EPS Q/Q-65.23%
Dividend-Sales Q/Q7.71%
Insider Own29.70%Inst Own45.97%
Insider Trans-11.89%Inst Trans11.99%
Short Float2.42%Earnings-
Analyst Recom-Target Price-
Avg Volume66.77K52W Range7.06 - 16.62
Kingsway Financial Services, Inc. operates as a holding company. The firm engages in the provision of financial services. It operates through the following segments: Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment includes excellent businesses in the Automotive and HVAC markets. It continues to expand its portfolio of high-quality operating companies through organic growth and disciplined M&A. The Kingsway Search Xcelerator segment is involved in review of billing rates and product prices are performed regularly and rates can be adjusted to reflect prevailing marketing expectations. The company was founded on September 19, 1989 and is headquartered in Chicago, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STILWELL JOSEPHDirectorJun 27 '25Sale14.03128,2431,799,596487,713Jul 01 05:52 PM
STILWELL JOSEPHDirectorJun 30 '25Sale13.9032,978458,556481,817Jul 01 05:52 PM
Fitzgerald John Taylor MaloneyPresident and CEOJul 01 '25Buy14.021792,5101,529,876Jul 01 04:52 PM
Hansen Kent ACFO & EVPJul 01 '25Buy14.021111,556135,248Jul 01 04:51 PM
Hansen Kent ACFO & EVPJun 13 '25Buy13.771141,570135,137Jun 16 04:00 PM
SWZ - Total Return Securities Fund - Stock Price Chart
TickerSWZ [NYSE]
CompanyTotal Return Securities Fund
CountryUSA
IndustryClosed-End Fund - Foreign
Market Cap81.58MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend4.55%Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float0.10%Earnings-
Analyst Recom-Target Price-
Avg Volume81.43K52W Range5.09 - 6.71
The Swiss Helvetia Fund Inc. is a closed-ended equity mutual fund launched and managed by Schroder Investment Management North America Inc. The fund invests in public equity markets of Switzerland. It seeks to invest in stocks of companies operating across diversified sectors. The fund primarily invests in value stocks of companies across all market capitalizations. It employs fundamental analysis with a bottom-up stock picking approach, focusing on factors such as capital appreciation, income, economic and industry trends, quality of management, financial condition, business plan, industry and sector market position, dividend payout ratio, and corporate governance to create its portfolio. The fund benchmarks the performance of its portfolio against the S&P 500 Index and MSCI EAFE Index. It was previously known as The Helvetia Fund, Inc. The Swiss Helvetia Fund Inc. was formed in October 24, 1986 and is domiciled in the United States.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SELL MORITZ ADirectorJun 30 '25Buy6.341,81511,5073,400Jul 01 04:39 PM
HELLERMAN GERALDDirectorApr 02 '25Sale9.24413795,283Apr 03 04:05 PM
GOLDSTEIN PHILLIPDirectorJan 17 '25Sale8.454,53538,32112,248Jan 21 04:14 PM
SPG - Simon Property Group, Inc - Stock Price Chart
TickerSPG [NYSE, S&P 500]
CompanySimon Property Group, Inc
CountryUSA
IndustryREIT - Retail
Market Cap62.24BEPS (ttm)6.69
P/E24.66EPS this Y-12.44%
Forward P/E24.06EPS next Y7.91%
PEG-EPS past 5Y2.13%
P/S10.38EPS next 5Y-1.55%
P/B21.00EPS Q/Q-38.19%
Dividend5.14%Sales Q/Q2.11%
Insider Own0.93%Inst Own92.74%
Insider Trans0.14%Inst Trans2.33%
Short Float1.09%EarningsMay 12/a
Analyst Recom2.10Target Price183.06
Avg Volume1.78M52W Range136.34 - 190.13
Simon Property Group, Inc. is a self-administered and self-managed real estate investment trust, which engages in the ownership, development, and management of shopping, dining, entertainment, and mixed-used destinations, which consist primarily of malls, Premium Outlets, and the Mills. The company was founded by Fred Simon, Herbert Simon and Melvin Simon in 1993 and is headquartered in Indianapolis, IN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STEWART MARTA RDirectorJun 30 '25Buy159.2920833,13216,080Jul 01 04:30 PM
Smith Daniel C.DirectorJun 30 '25Buy159.2937860,21231,998Jul 01 04:28 PM
SELIG STEFAN MDirectorJun 30 '25Buy159.2921934,88531,881Jul 01 04:26 PM
Roe Peggy FangDirectorJun 30 '25Buy159.298613,6996,650Jul 01 04:23 PM
RODKIN GARY MDirectorJun 30 '25Buy159.2924639,18519,010Jul 01 04:21 PM
CDXS - Codexis Inc - Stock Price Chart
TickerCDXS [NASD, RUT]
CompanyCodexis Inc
CountryUSA
IndustryBiotechnology
Market Cap213.74MEPS (ttm)-0.99
P/E-EPS this Y22.15%
Forward P/E-EPS next Y17.01%
PEG-EPS past 5Y-33.31%
P/S4.29EPS next 5Y41.30%
P/B4.31EPS Q/Q-52.40%
Dividend-Sales Q/Q-55.82%
Insider Own3.23%Inst Own83.26%
Insider Trans140.25%Inst Trans7.29%
Short Float7.93%EarningsMay 14/a
Analyst Recom1.57Target Price7.08
Avg Volume851.34K52W Range1.90 - 6.08
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Opaleye Management Inc.10% OwnerJun 27 '25Buy2.39100,000239,00012,350,000Jul 01 04:05 PM
Opaleye Management Inc.10% OwnerJun 12 '25Buy2.25100,000225,00012,100,000Jun 16 04:59 PM
Opaleye Management Inc.10% OwnerJun 13 '25Buy2.2399,102220,99712,199,102Jun 16 04:59 PM
Opaleye Management Inc.10% OwnerJun 16 '25Buy2.2450,898114,01212,250,000Jun 16 04:59 PM
Opaleye Management Inc.10% OwnerMay 23 '25Buy2.362,320,0005,475,20011,995,000May 28 04:05 PM
OCSL - Oaktree Specialty Lending Corp - Stock Price Chart
TickerOCSL [NASD]
CompanyOaktree Specialty Lending Corp
CountryUSA
IndustryAsset Management
Market Cap1.22BEPS (ttm)0.12
P/E115.42EPS this Y-16.65%
Forward P/E8.24EPS next Y-9.54%
PEG-EPS past 5Y-
P/S3.45EPS next 5Y-
P/B0.83EPS Q/Q-
Dividend13.83%Sales Q/Q-17.50%
Insider Own0.30%Inst Own38.29%
Insider Trans19.29%Inst Trans-
Short Float1.38%EarningsMay 01/b
Analyst Recom2.71Target Price14.30
Avg Volume727.58K52W Range12.50 - 18.70
Oaktree Specialty Lending Corporation is a business development company. The fund specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity, and management buyouts in small and mid-sized companies. It seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering. The firm also seeks investment in media, advertising sectors, software, IT services, pharmaceuticals, biotechnology, real estate management and development, chemicals, machinery, and internet and direct marketing retail sectors. It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies. The firm invest in companies having enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million. The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America. The fund seeks to be a lead investor in its portfolio companies.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gero Deborah AnnDirectorJun 30 '25Buy13.702,50034,25022,411Jul 01 04:05 PM
Panossian ArmenSee RemarksMay 15 '25Buy14.138,000113,04020,789May 19 06:06 AM
CALDWELL PHYLLIS RDirectorMay 07 '25Buy13.322,00026,65018,000May 08 06:03 AM
Jacobson Craig ADirectorMay 06 '25Buy13.4114,910199,91971,667May 07 04:10 PM
CALDWELL PHYLLIS RDirectorFeb 25 '25Buy15.832,50039,57516,000Feb 26 04:15 PM
PRME - Prime Medicine Inc - Stock Price Chart
TickerPRME [NASD, RUT]
CompanyPrime Medicine Inc
CountryUSA
IndustryBiotechnology
Market Cap498.92MEPS (ttm)-1.66
P/E-EPS this Y23.33%
Forward P/E-EPS next Y20.83%
PEG-EPS past 5Y-124.13%
P/S129.59EPS next 5Y18.30%
P/B4.66EPS Q/Q9.47%
Dividend-Sales Q/Q146.02%
Insider Own60.65%Inst Own28.99%
Insider Trans0.41%Inst Trans-6.37%
Short Float35.79%EarningsMay 08/b
Analyst Recom1.73Target Price7.69
Avg Volume2.56M52W Range1.11 - 6.75
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Liu David R.10% OwnerJun 30 '25Buy2.5221,00052,83020,240,945Jul 01 04:03 PM
Liu David R.10% OwnerJun 23 '25Buy2.1621,00045,40220,219,945Jun 23 04:33 PM
Liu David R.10% OwnerJun 16 '25Buy1.4921,00031,19620,198,945Jun 16 05:14 PM
Liu David R.10% OwnerJun 11 '25Buy1.6021,00033,59020,177,945Jun 12 04:49 PM
Brudnick RichardChief Business OfficerMay 20 '25Buy1.1920,00023,79020,000May 22 04:22 PM
PLUR - Pluri Inc - Stock Price Chart
TickerPLUR [NASD]
CompanyPluri Inc
CountryIsrael
IndustryBiotechnology
Market Cap45.35MEPS (ttm)-3.61
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y29.51%
P/S44.03EPS next 5Y33.58%
P/B-EPS Q/Q7.62%
Dividend-Sales Q/Q501.41%
Insider Own46.69%Inst Own17.39%
Insider Trans36.42%Inst Trans119.45%
Short Float0.80%EarningsMay 08
Analyst Recom1.00Target Price12.00
Avg Volume36.92K52W Range3.33 - 7.13
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manieu Alexandre WeinsteinDirectorApr 28 '25Buy4.61976,1394,500,001931,246Jul 01 04:00 PM
EONR - EON Resources Inc - Stock Price Chart
TickerEONR [AMEX]
CompanyEON Resources Inc
CountryUSA
IndustryOil & Gas E&P
Market Cap7.37MEPS (ttm)-0.89
P/E-EPS this Y75.13%
Forward P/E-EPS next Y40.67%
PEG-EPS past 5Y-
P/S0.38EPS next 5Y-
P/B0.60EPS Q/Q87.26%
Dividend-Sales Q/Q-11.94%
Insider Own33.83%Inst Own1.76%
Insider Trans-13.25%Inst Trans-24.76%
Short Float12.98%EarningsMay 23/b
Analyst Recom1.00Target Price2.00
Avg Volume5.46M52W Range0.33 - 2.92
EON Resources, Inc. engages in the acquisition, development, exploration, production, and divestiture of oil and natural gas properties in the Permian Basin. The company was founded in February 2017 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Salvucci Joseph V SrDirectorJun 30 '25Buy0.34123,95141,9571,629,121Jul 01 03:30 PM
Salvucci Joseph V JrDirectorJun 27 '25Buy0.3515,0005,217147,784Jun 30 03:30 PM
Salvucci Joseph V SrDirectorJun 27 '25Buy0.37100,00036,6401,505,170Jun 30 11:23 AM
Caravaggio DanteChief Executive OfficerJun 27 '25Buy0.353,0001,045564,440Jun 27 05:35 PM
Trotter MitchellChief Financial OfficerJun 27 '25Buy0.3515,0005,23254,398Jun 27 03:14 PM
12345678910